Brief: Medivir's MIV-711 Granted Orphan Drug Designation By FDA
27/11/2025 10:44
Nov 27 (Reuters) - Medivir AB MEDIVIR.ST: FDA GRANTS MEDIVIR'S MIV-711 ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF OSTEOGENESIS IMPERFECTA DESIGNATION PROVIDES ASSISTANCE IN DEVELOPING DRUGS, TAX CREDITS, EXEMPTIONS FROM FDA FEES AND 7 YEARS OF MARKETING EXCLUSIVITY MIV-711 IS MEDIVIR'S SELECTIVE CATHEPSIN K INHIBITOR TARGETING TREATMENT OF OSTEOGENESIS IMPERFECTA Source text: ID:nMFN2drsP Further company coverage: MEDIVIR.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))